Pharmacokinetic, pharmacodynamic and biomarker evaluation of transforming growth factor-β receptor I kinase inhibitor, galunisertib, in phase 1 study in patients with advanced cancer by Rodón, Jordi et al.
PHASE I STUDIES
Pharmacokinetic, pharmacodynamic and biomarker evaluation
of transforming growth factor-β receptor I kinase inhibitor,
galunisertib, in phase 1 study in patients with advanced cancer
Jordi Rodón & Michael Carducci & Juan M. Sepulveda-Sánchez & Analía Azaro &
Emiliano Calvo & Joan Seoane & Irene Braña & Elisabet Sicart & Ivelina Gueorguieva &
Ann Cleverly & N. Sokalingum Pillay & Durisala Desaiah & Shawn T. Estrem &
Luis Paz-Ares & Matthias Holdhoff & Jaishri Blakeley & Michael M. Lahn & Jose Baselga
Received: 19 September 2014 /Accepted: 24 November 2014 /Published online: 23 December 2014
# The Author(s) 2014. This article is published with open access at Springerlink.com
Summary Purpose Transforming growth factor-beta
(TGF-β) signaling plays a key role in epithelial-
mesenchymal transition (EMT) of tumors, including malig-
nant glioma. Small molecule inhibitors (SMI) blocking
TGF-β signaling reverse EMT and arrest tumor progression.
Several SMIs were developed, but currently only LY2157299
monohydrate (galunisertib) was advanced to clinical investi-
gation. Design The first-in-human dose study had three parts
(Part A, dose escalation, n=39; Part B, safety combination
with lomustine, n=26; Part C, relative bioavailability study,
n = 14) . Resul t s A prec l in ica l pharmacokine t ic /
pharmacodynamic (PK/PD) model predicted a therapeutic
window up to 300 mg/day and was confirmed in Part A after
continuous PK/PD. PK was not affected by co-medications
such as enzyme-inducing anti-epileptic drugs or proton pump
inhibitors. Changes in pSMAD2 levels in peripheral blood
mononuclear cells were associated with exposure indicating
target-related pharmacological activity of galunisertib. Twelve
(12/79; 15 %) patients with refractory/relapsed malignant
glioma had durable stable disease (SD) for 6 or more cycles,
partial responses (PR), or complete responses (CR). These
patients with clinical benefit had high plasma baseline levels
of MDC/CCL22 and low protein expression of pSMAD2 in
their tumors. Of the 5 patients with IDH1/2 mutation, 4
patients had a clinical benefit as defined by CR/PR and SD
≥6 cycles. Galunisertib had a favorable toxicity profile and no
cardiac adverse events. Conclusion Based on the PK, PD, and
biomarker evaluations, the intermittent administration of
galunisertib at 300 mg/day is safe for future clinical
investigation.
The data from this study were presented in part at ASCO 2008, ASCO
2011, ASCO 2012, and ASCO 2013.
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Introduction
Transforming growth factor-beta (TGF-β) ligands (TGF-β1,
TGF-β2, TGF-β3) regulate diverse biological functions [1,
2]. Any of these three ligands can engage the specific receptor
TGF-βRI, which then heterodimerizes with TGF-βRII. This
heterodimer complex phosphorylates the intracellular proteins
SMAD2 and SMAD3 that activates a signaling cascade to
induce several nuclear transduction proteins. With the induc-
tion of such proteins, the TGF-β signaling pathway influences
cellular proliferation, differentiation, motility, survival and
apoptosis in tumor cells. This can promote epithelial-
mesenchymal transition (EMT) of a tumor, including malig-
nant glioma, making TGF-β signaling a key driver of tumor
progression [3, 4]. Patients with glioma who receive
trabedersen, an antisense oligonucleotide designed to block
TGF-β2 [5], show clinical benefit suggesting that blocking
this pathway may result in anti-tumor activity.
Like trabedersen, the TGF-βRI kinase small molecule
inhibitor (SMI) LY2157299 monohydrate (galunisertib) was
developed to block the TGF-β signaling in cancer [6]. Be-
cause galunisertib is the first SMI to be clinically investigated
in patients, a predictive pharmacokinetic/pharmacodynamic
(PK/PD) model was developed to identify a safe therapeutic
window for the first-in-human dose (FHD) study [7]. In the
FHD study, the predictions from the PK/PD model were
confirmed after PK profiles and PD assessments were obtain-
ed from patients in each cohort [8]. The PD assessments were
based on a previously developed enzyme-linked immunosor-
bent assay (ELISA) that measured changes of the phosphory-
lated SMAD2 (pSMAD2) [9]. In addition, we evaluated other
baseline biomarkers in plasma and in tumor tissue as future
candidates for prognostic or predictive markers of TGF-β
inhibitors [10]. Among these baselinemarkers, we determined
whether the patients with IDH1/2 mutations had either radio-
graphic responses or stable disease (SD). In addition, we
investigated whether baseline high plasma MDC/CCL22
levels were associated with clinical benefit.
Methods
Patients
Patients were eligible to participate in the study if they had a
histologic or cytologic diagnosis of cancer, progressed on
previous therapies and had measurable tumors. Starting with
Cohort 3, only patients with relapsed and progressive glioma
were eligible for this study. All patients were assessed for
radiographic responses using Response Evaluation Criteria
in Solid Tumors (RECIST) and, for glioma patients, using
Macdonald criteria [11]. All patients had to have an Eastern
Cooperative Oncology Group performance status of ≤2. Pa-
tients were required to have adequate hematologic, hepatic,
and renal function and discontinue all previous therapies for
cancer at least 4 weeks prior to study enrollment. Exclusion
criteria included medically uncontrolled cardiovascular ill-
ness, electrocardiogram anomalies, serious pre-existing med-
ical conditions, and any unapproved therapy.
The study was conducted according to the principles of
good clinical practice, applicable laws and regulations, and the
Declaration of Helsinki. Each institution’s review board ap-
proved the study and all patients signed an informed consent
document before study participation.
Study design
Galunisertib was evaluated in a 3-part, multicenter, open-
label, nonrandomized, dose-escalation first-in-human Phase I
study.
Part A was a dose escalation study using galunisertib
monotherapy administered initially to patients with ad-
vanced or metastatic cancer as a daily continuous dosing.
Starting with Cohort 3 and for the remainder of the study,
patients received galunisertib on an intermittent dose
regimen of 14 days on/14 days off for a 28-day cycle.
Part B was a safety study using galunisertib on an
intermittent dose regimen at 160 mg/day (80 mg twice
daily [BID]) and 300 mg/day (150 mg BID) in combina-
tion with lomustine given once every 6 weeks in patients
with recurrent malignant glioma who had previously
failed approved treatments.
Part C was a relative bioavailability (RBA) crossover
study conducted at only one center to assess two new
formulations (publication in preparation). All patients
were then eligible to continue on 300 mg/day dosing. In
this part of the study, patients with different tumor histol-
ogies were eligible to participate; the majority of patients
had glioma. The only results from Part C presented in this
publication are the results of the T cell subset examina-
tion. Other results will be published elsewhere.
Study objectives
The objectives of this study were to characterize the PK
profile of galunisertib monotherapy (Part A) and galunisertib
in combination with lomustine (Part B). In addition, the rela-
tionship of pSMAD2 to galunisertib exposure was assessed
(Part A). Biomarkers in plasma and tissue were sampled at
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baseline and during treatment to identify possible prognostic
or predictive biomarkers.
Treatment
In Part A, galunisertib was given orally BID at doses of 20 mg
(40 mg/day), 40 mg (80 mg/day), 80 mg (160 mg/day), 120
(240 mg/day) and 150 mg (300 mg/day). In Part B, patients in
Cohort 1 received galunisertib at 160 mg/day on intermittent
dosing as defined in Part A. Lomustine 100 to 130 mg/m2 was
given orally once every 6 weeks beginning 1 week after initial
galunisertib dosing. In Cohort 2, 300 mg/day of galunisertib
was given on an intermittent dosing schedule and lomustine as
in Cohort 1. In Part C, all patients received 300 mg/day
monotherapy of galunisertib.
Bioanalytical methods
Human plasma samples obtained during this study were ana-
lyzed at PharmaNet USA, Inc. Princeton, New Jersey, USA.
The samples were analyzed for galunisertib levels using 2
validated liquid chromatography with tandemmass spectrom-
etry methods. For the high-range method (PharmaNet USA,
Inc. SOP TM.589), the lower limit of quantification was
5.000 ng/mL and the upper limit of quantification was
1000.000 ng/mL. The intra-assay accuracy (% relative error)
during validation ranged from 1.800 to 10.222 %. The intra-
assay precision (% relative standard deviation) during valida-
tion ranged from 3.119 to 18.389 %. Samples above the limit
of quantification were diluted to yield results within the cali-
brated range. Samples below the lower limit of quantification
using the high-range method were reanalyzed using the low-
range method. For the low-range method (PharmaNet USA,
Inc. SOP TM.563), the lower limit of quantification was
0.050 ng/mL and the upper limit of quantification was
10.000 ng/mL. The intra-assay accuracy during validation
ranged from −5.080 to −2.000 %. The intra-assay precision
during validation ranged from 4.404 to 12.245 %.
Pharmacokinetic methods
All patients who received at least 1 dose of galunisertib and
had samples collected were subjected to PK analyses. The PK
parameters for galunisertib were computed by standard non-
compartmental methods of analysis using Win Nonlin Profes-
sional Edition (version 5.3) on a computer that met or
exceeded the minimum system requirements for this program
with appropriate and validated software. The parameters re-
ported from the non-compartmental analyses included the
maximum plasma concentration (Cmax), area under the
curve from zero to 24 h (AUC(0–24)), AUC from zero time
to infinity (AUC(0-∞)), half-life volume of distribution
(Vd) and clearance (CL).
Pharmacodynamics pSMAD2 ELISA
pSMAD2 in peripheral blood mononuclear cells (PBMCs)
were assessed by a specific ELISA as previously described
[9], in which a rabbit polyclonal antibody recognizing
pSMAD2 was used. Total SMAD2 was also assessed and
used to normalize the expression of pSMAD2.
Flow cytometry for T cell subsets
Blood samples were obtained and prepared for flow cytometry
assessment following the instructions of Quintiles Laborato-
ries (Durham, NC). After red blood cell lysis, cells were
stained for CD3+, CD8+, CD4+ and CD4+CD25+ CD127−/
LOFoxp3+ and events were collected by flow cytometer per
standard Quintiles procedures. All results were reported as
absolute cell counts and as percentage of lymphocytes.
Baseline biomarker assessments
Plasma samples were analyzed for PD assessments by using a
multi-analyte immunoassay panel (MAIP) (Myriad RBM,
Austin, TX). The MAIP measurements included 89 plasma
proteins [10]. These proteins were evaluated at baseline and
during the first cycle of treatment.
Tumor tissue from the initial pathological diagnosis was
obtained and slides for immunohistochemistry (IHC) staining
were sent to Ventana (Tucson, AZ). All slides were stained for
pSMAD2 (Ser465/467, 138D4, Rabbit mAb) following rec-
ommendation by the manufacturer (Cell Signaling, MA).
Genetic mutation assessments (including IDH1/2) were
conducted at Foundation Medicine (New York, NY) follow-
ing previously described sequencing and analysis approach
[11]. DNAwas extracted, sequenced, and 287 genes assessed
for point mutations, short insertions/deletions, copy number
alterations, and re-arrangements.
Statistical analyses
A power model was fitted to PK parameter estimates Cmax and
AUC(0–24) to assess the extent of dose proportionality. Clinical
benefit in this study has been defined as a patient with either a
complete response (CR), partial response (PR), and stable
disease (SD) ≥6 cycles [8].MAIP results from plasma samples
taken at baseline were compared between patients completing
>6 cycles and ≤6 cycles using ANOVA. The analysis included
controlling the false discovery rate to 30 % using the
Benjamini-Hochberg method. Boxplots showing the distribu-
tions at baseline of the potentially prognostic markers are
provided. Observed TGF-β-s t imulated pSMAD2
(pSMAD2+) in PBMCs was normalized by TGF-β-
stimulated tSMAD2 [(tSMAD2+) 0.6[9,10]] prior to determin-
ing the minimum normalized pSMAD2+ and calculating
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percentage inhibition post-baseline for each patient. Baseline
and minimum post-baseline values for each patient together
with maximum percentage inhibition are presented on a line
and scatter plot for each patient in Cohort 3 and summary
statistics by time point provided from a standard mixed effects
regression model, fitting log normalized pSMAD2+ to the
fixed effects of log baseline normalized pSMAD2+, nominal
time point, dose and their interaction and patient as a random
effect.
No statistical analyses were performed on IHC scores of
pSMAD2 in tissue, T cells and lymphocytes. The former are
summarized using box whisker plots and the latter are
displayed in line and scatter plots.
Results
FHD study design and patient characteristics
In this three-part FHD study, 79 patients were enrolled.
The details of the study design and patient demographics
have been reported elsewhere [8], but a brief description
is provided here. The study started in 2006 and was
closed in 2012. In Part A (galunisertib monotherapy,
dose-escalation), 39 patients were enrolled: in Cohort 1
(40 mg/day) and Cohort 2 (80 mg/day), 7 patients with
advanced or metastatic cancer, and 32 patients with glio-
ma in Cohorts 3, 4, and 5. In Part B (galunisertib com-
bined with lomustine), 26 patients received galunisertib in
combination with lomustine. In Part C (RBA followed by
monotherapy), 14 patients (9 patients with glioma) com-
pleted the RBA study and elected to continue galunisertib
treatment. Most patients with glioma had primary Grade
IV glioblastoma (50 % in Part A, 76.9 % in Part B, not
collected in Part C). However, in Part A there were more
patients with secondary glioblastoma or low-grade glioma
compared to Part B (Table 1). As of June 2014, 3 patients
were still receiving galunisertib: 2 in Part A (treated for
73 and 55 cycles respectively, or 5 and 4.2 years, respec-
tively) and 1 in Part B (treated for 48 cycles or 3.7 years).
Pharmacokinetic measures
Part A (Fig. 1 and Table 2): Non-compartmental PK
analysis was performed on 37 of the 39 patients treated
in Part A: n=3 in Cohort 1 (40 mg/day); n=4 in Cohort 2
(80 mg/day); n=15 in Cohort 3 (160 mg/day); n=6 in
Cohort 4 (240 mg/day); n=9 in Cohort 5 (300 mg/day).
Results showed rapid absorption of galunisertib, as dem-
onstrated by measurable plasma concentrations for at
least 48 h. The terminal half-life was approximately 8 h.
At steady state, on Day 14, the median time to maximum
concentration (tmax,ss) ranged from 0.5 to 2 h post dose,
independent of dose. Formal assessment of time-linear
kinetics was not possible, regardless of whether or not the
observed exposures of AUC(0-∞) Day 1 and AUC(0-∞)
Day 14 were similar. However, no accumulation of
galunisertib in the 5 cohorts was observed over the 14-
day BID dosing regimen. Both the maximum observed
plasma concentration at steady state (Cmax,ss) and expo-
sure increased with dose as indicated from the statistical
analysis of the PK parameters. The estimated ratios of
geometric means for the AUC(0-∞) and Cmax,ss between
40 and 300 mg daily (7.5-fold) were 5.61 (90 % confi-
dence intervals [CI]: 3.80, 8.30) and 3.99 (90 % CI: 2.43,
6.54), respectively. For a doubling of dose, the fold
increases for AUC(0-∞) and Cmax,ss were 1.81-fold with
corresponding 90 % CI (1.58, 2.07) and 1.61-fold with
90 % CI (1.36, 1.91), respectively. This suggests dose-
proportional PK for any doubling of dose within the
studied dose range of 40–300 mg, particularly for
AUC(0-∞). Within- and between-patient coefficients of
variation were estimated as 29 and 42 %, respectively,
for AUC(0-∞) at steady state, and 31 and 55 %, respec-
tively, for Cmax,ss, all pooled across the 5 cohorts from the
dose-proportionality analysis. A population PK model
was developed based on data in Cohorts 1 through 5
[7]. The mean population CL of galunisertib was 38 L/
h, and the steady state volume of distribution (Vss) was
210 L.
Part B: Patients were administered lomustine in combi-
nation with galunisertib. PK profiles of galunisertib fol-
lowing administration of 160 mg/day (Cohort 6) and
300 mg/day (Cohort 7) on Days 6 and 7 were similar.
Hence, co-administration of lomustine did not appear to
alter the galunisertib PK profile.
Pharmacokinetics in patients receiving enzyme-inducing
and nonenzyme-inducing anti-epileptic drugs and proton
pump inhibitors
Patients with glioblastoma received several drugs that
help control epileptic events, specifically carbamazepine,
felbamate, oxcarbazepine, phenobarbital, phenytoin, and
topiramate. These drugs are known to alter PK profile of
therapeutic agents, especially if such agents are metabo-
lized via the liver. One such example has been reported on
imatinib in the treatment of glioblastoma [12]. In this
study, 3 patients (2 in Cohort 3 and 1 in Cohort 4)
received galunisertib while on an enzyme-inducing med-
ication. The PK profiles of these patients (shown by
broken grey lines in Fig. 1a and b) do not appear to differ
from the other patients. Additionally, PK profiles of pa-
tients who were on proton pump inhibitors (PPIs) were
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plotted together with remaining patients to investigate any
influence on galunisertib exposure. The most common
PPI prescribed to patients was omeprazole. Fourteen pa-
tients (1 in Cohort 2, 6 in Cohort 3, 4 in Cohort 4, and 3
in Cohort 5) received galunisertib while on a PPI medi-
cation. The PK profiles of these patients (shown by bro-
ken grey lines in Fig. 1c, d, and e) do not appear to be
altered by co-administration with PPIs.
Pharmacodynamic evaluation
Using an ELISA to detect changes of pSMAD2 in isolated
PBMCs as a PD response marker [9], we observed chang-
es after galunisertib administration. Results from Cohort 3
(n=14 patients) were used to confirm reduction of
pSMAD2 levels in PBMCs because this cohort had a
sufficient number of patients to assess the PK and PD
relationship during dose escalation. In 11 of the 14
patients, pSMAD2 inhibition was assessed at the observed
maximum concentration for galunisertib about 2–6 h after
administration on Day 14 of the first cycle. In 6 of the 11
patients, pSMAD2 levels were reduced in relationship to
drug concentration, while in the remaining 5 patients,
there was no relationship at the expected Cmax (Fig. 2a).
A reduction in pSMAD2 was observed in 9 (64 %) of the
14 patients during the first 14 days of treatment (Fig. 2b).
For 2 patients, this trend was observed in both Cycles 1
and 2 (not shown). Once the drug was stopped after
14 days of administration, pSMAD2 changes were
assessed for the next 3 days in 2 patients, one in Cohort
1 and 1 in Cohort 3 (Fig. 2c and d). The pSMAD2
inhibition was still present although drug levels were
low or undetectable. The mean of the observed percentage
inhibition of normalized pSMAD2+ from Cycle 1 Day 1








Mean (SD) 51.8 (14.88) 44.5 (10.35) 59.8
Median (Range) 54 (22–77) 43.5 (25–61) 56.5 (34–76)
Sex, n (%)
Male 30 (76.9) 19 (73.1) 5 (35.7)
Female 9 (23.1) 7 (26.9) 9 (64.3)
ECOG, n (%)
0 15 (38.5) 3 (11.5) 4 (28.6)
1 19 (48.7) 17 (65.4) 8 (57.1)
2 5 (12.8) 6 (23.1) 2 (14.3)
Number of prior regimens, n (%)
1 17 (43.6) 7 (26.9) 2 (14.3)a
2 13 (33.3) 11 (42.3) 4 (28.6)a
3 4 (10.3) 7 (26.9) 2 (14.3)a
>3 5 (12.8) 1 (3.8) 1 (7.1)a
Patients with glioma only N=32 N=26 N=9
Time from initial diagnosis to before first dose, median
(range: earliest to most recent) in months
22.1 (172.4−2.8) 18 (154.6−7.0) Not collected
Glioma WHO, at study entry, n (%) n=30 n=26 Not collected
Grade I 1 (3.3) –
Grade II 2 (6.7) –
Grade III 6 (20) 4 (15.4)
Grade IV 21 (70) 22 (84.6)
Secondary grade IV 6 (20) 2 (7.7)
Primary grade IV 15 (50) 20 (76.9)
Tissue samples for deep sequencing n=11 n=10 Not collected
IDH1/2 mutation, n (%) 3 (27.3) 2 (20)
a Glioma patients only (Part C)
Abbreviations: ECOG eastern cooperative oncology group, WHO world health organization
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and Day 12 for Cohort 3 together with the estimated
means from the model are provided in Table 2.
Changes in T cell subsets
An amendment was introduced to assess T cell subsets in Part
B and Part C. Some patients receiving the combination of
galunisertib and lomustine had a reduction in lymphocyte
counts consistent with bone marrow toxicity related to
lomustine as evidenced by platelet and neutrophil reduction
(Fig. 3a). In contrast, patients in Part C who received more
than 2 cycles of treatment showed no comparable bone mar-
row toxicity as neutrophils and platelets were unchanged
(Fig. 3b) and lymphocyte counts were stable. In Part B,
lymphocyte counts and the respective subsets were reduced,
while in Part C the counts either stabilized or increased for
CD3+, CD8+, CD4+, and CD4+CD25+CD127−/LOFoxp3+
cells (Fig. 3).
Baseline tumor tissue evaluation
In order to interpret protein and gene expression as potential
prognostic factors we used the concept of clinical benefit
based on radiographic response and/or stable disease for
≥6 cycles (Table 3).
Baseline pSMAD2 expression was assessed in tumor tissue
from the original tumor biopsy for 50 patients with glioma by
IHC. The majority of the patients had an H-score below 100,
and the observed pSMAD2 tumor expression was lower in
patients who were treated for ≥6 cycles: H-score median (1st;
Fig. 1 Pharmacokinetic profile of galunisertib at Day 14 (Part A) across
doses of 80 mg BID, 120 mg BID and 150 mg BID. Co-medication of
EIAE drugs (panels a and b): In Part A, 3 patients (2 in Cohort 3 and 1 in
Cohort 4) received galunisertib while being on an EIAE medication. The
PK profile of these patients (shown by broken grey lines) does not appear
to differ from the other patients. Co-medication with PPIs (panels c-e):
Plasma galunisertib individual concentration time profiles for all patients
and patients on PPIs plotted on Day 14 following oral doses of 80 mg
(160 mg/day), 120 mg (240 mg/day), and 150 mg (300 mg/day) BID.
Fourteen patients (1 in Part A Cohort 2 [40mg BID]; 6 in Part A Cohort 3
[80mgBID], panel c; 4 in Part A Cohort 4 [120mg BID], panel d; and 3
in Part A Cohort 5 [150 mg BID], panel e) received galunisertib while on
a PPI medication. The PK profile of these patients (shown by broken grey
lines) does not appear to differ from the other patients. Abbreviation: BID
twice daily, EIAE enzyme-inducing anti-epileptic, PK pharmacokinetic,
PPI proton pump inhibitors
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Observations mean (% CV), day 14, steady state
Cycle 1 Cycle 2
Cmax, ss (ng/mL) AUC0,∞ (ng*h/mL) Cmax, ss (ng/mL) AUC0,∞ (ng*h/mL)
40 3 - NA 220 (92) 518* (60) NA NA
80 4 - NA 350 (44) 1310* (41) NA NA
160 13−9 630 (58) 2140 (52) 790 (51) 2430 (33)




300 9−7 990 (57) 3730 (46) 800 (58) 2930 (63)
Percent Inhibition of pSMAD2 (normalizedb) at the 160 mg/day cohort (Part A):
Observed, fitted Percentage Inhibition of Normalizedb pSMAD2 – (N), (95 % CI)
Day 1 Day 12 or 15
0.5 4 6 Post Dose
26 %, 27 %
(13), (−43, 62)
5 %, 5 %
(14), (−82, 51)
−10 %, −10 %
(14), (−112, 43)
39 %, 34 %
(15), (−26, 65)
Abbreviations: CI confidence interval, h hour, pSMAD phosphorylated SMAD2, tSMAD total SMAD
a Individual parameters (n <3), b pSMAD2 is normalized by dividing pSMAD2+ by tSMAD2+ to the power of 0.6. Note: The time point “Post dose, Day
12/15” includes 2, 3, 4, 6 h Day 12 for 160 mg. The fitted results are derived from the mixed-effects model
Fig. 2 Pharmacodynamic effect of galunisertib. Panel a: Pre-dose
normalized pSMAD2 vs minimum post-dose pSMAD2 (left axis) and
maximum percentage inhibition of normalized pSMAD2 (right axis).
Percent inhibition observed in most patients ranged from 10 to 100 %
(Part A glioma patients only). Panel b: pSMAD2 inhibition is plotted in
relationship to concentration on the last day of dosing (Day 14) of the first
cycle. Panel c and d: pSMAD2 inhibition (solid circles) is shown in
relationship to the concentrations (open circles) in hours after galunisertib
administration was stopped (336 h=14 days) for 2 patients (Cohort 1:
panel c, Cohort 3: panel d)
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3rd quartiles) was 47.5 (12;75) for patients treated for ≥6 cy-
cles and for patients treated for <6 cycles it was 75
(27.5;122.5). However, there was no statistical difference
between both groups (p=0.222). Genes were sequenced in
24 samples from patients with glioma in Part A and Part B, of
which 21 (21/58; 36 %) had sufficient tumor material (2
samples had no tumor and 1 sample had insufficient material).
Gene alteration data were obtained for 11 patients in Part A
and 10 patients in Part B (Table 3). On average, there were 4
known/likely functional mutations or 14 variants including
alterations of unknown functional significance across 21 tu-
mor samples (data not shown). Of the 21 patients, 7 (33 %)
samples were from patients with clinical benefit and 14 (67%)
from those with no clinical benefit. Among these 21 samples,
there were 8 from patients with either a secondary glioblasto-
ma or low-grade glioma and 13 with a primary glioblastoma.
Genetic alterations were retrospectively evaluated by compar-
ing patients with clinical benefit versus no clinical benefit
(CR/PR and SD ≥6 cycles versus those receiving <6 cycles
of galunisertib) (Tables 3, 4).
Of the 8 patients with secondary or low-grade glioma, 5
(5/8;62 %) had an isocitrate dehydrogenase (IDH) 1 or IDH2
mutation (Table 3), and 4 of these 5 showed clinical benefit,
while none of the 3 low-grade or secondary gliomas without
IDH mutations showed radiographic responses or SD ≥6 cy-
cles. Among the 13 patients with primary glioblastoma, none
Fig. 3 Counts of lymphocytes,
erythrocytes, neutrophils and
platelets in patients (as
represented by individual lines) of
Part B (combination of
galunisertib and lomustine, panel
3a) and Part C (monotherapy of
galunisertib, panel 3b).
Lymphocytes were reduced as
result of the lomustine treatment
compared to Part C (see for
comparison the effect on T cell
subset examination on Fig. 4).
Solid vertical lines indicate
galunisertib dosing
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had an isocitrate dehydrogenase IDH1 or IDH2 mutation, and
3 patients (3/13; 23 %) showed radiographic responses or SD
≥6 cycles.
Additionally, the results from this small data set indi-
cate that tumors containing epithelial growth factor re-
ceptor (EGFR) variants may not be responsive to
galunisertib. All 8 patients with tumors (8/8;100 %) con-
taining EGFR variants (2 in Part A and 6 in Part B) were
treated for <6 cycles, while patients with tumors not
containing the EGFR variant 54 % (7/13) were treated
for ≥6 cycles (Table 3). CDKN2A loss was an additional
variant exclusively observed in the nonresponsive tu-
mors. The CDK4 amplification was present in 1 patient
who responded, but mainly present in patients who did
not have a response or clinical benefit. Thus, having an
IDH1/2 variant was associated with a response, while
EGFR, CDKN2A, and CDK4 variants were associated
with a lack of response.
Baseline plasma protein evaluation
As previously described, an MAIP was used [13] to
determine plasma protein levels at baseline. It was ex-
pected that some plasma proteins would differentiate
patients receiving ≤6 cycles from those receiving >6 cy-
cles of galunisertib treatment (Fig. 5). In patients of Part
A and Part B, ferritin (panel a), IL-8 (panel b), apoli-
poprotein (panel c), vascular endothelial growth factor
(VEGF) (panel d), and lactate dehydrogenase (LDH)
(panel f) were lower in patients who were treated for
>6 cycles and elevated in patients treated for ≤6 cycles.
Only macrophage-derived chemokine (MDC or CCL22
[chemokine (c-c motif) ligand-22]) levels (panel e) were
higher at baseline for patients treated with galunisertib
longer than 6 cycles.
Discussion
Galunisertib treatment showed single-agent activity in
patients with glioma who had progressed on treatments
that were previously effective. Determined by radio-
graphic responses or durable disease stabilization for at
least 6 cycles of treatment, clinical benefit was seen in
12 of 79 (15 %) patients, all in glioma. The responses
also are reminiscent of those reported for patients with
glioma treated with trabedersen [5]. Similar to
trabedersen, the responses appeared to be more common
in patients with lower WHO grade glioma. Secondary or
lower-grade gliomas are commonly associated with IDH1
mutations [14, 15], and IDH1 mutations have been re-
cently associated with TGF-β signaling [16]. To further
investigate this possibility, we evaluated the remaining
tumor tissue for IDH1/2 mutation. Among the 5 patients
with an IDH1/2 mutated tumor, there were 4 with either
radiographic response or SD ≥6 cycles. One patient with
IHD1/2 mutation had no clinical benefit (CR, PR and SD
≥6 cycles). Besides these patients with IDH1/2 mutation,
3 other patients with primary glioma benefited from
galunisertib. Therefore, it is possible that TGF-β signal-
ing is enriched in the IDH1/2 population but is also
present in other subgroups of glioma. One such over-
arching phenotype may be characterized by the mesen-
chymal activation pathway [17].
Galunisertib affected the pSMAD2 expression in
PBMCs. Generally, percentage inhibition (compared to
pre-dose) of pSMAD2 concentrations in PBMCs were
more variable than expected ([10]) and was higher than
the variability used to size this study to detect a 50 %
pSMAD2 inhibition. Nevertheless, reductions post-dose
were observed in 64 % of patients in Cohort 3, and mean
percentage inhibition was estimated to be approximately
Fig. 4 T cell subset assessment after galunisertib treatment in
combination with lomustine (Part B) or as monotherapy (Part C).
Patients (as represented by individual lines) receiving more than
2 cycles of treatment showed a reduction across all T cell subsets if they
were treated with the combination of lomustine and galunisertib, but
showed stable T cell counts when receiving galunisertib alone
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40 % at the end of 14 days of treatment. There are some
observations suggesting that an indirect relationship be-
tween the exposure and pSMAD2 inhibition may exist
which is supported by pSMAD2 inhibition continuing
after the drug is stopped. Overall, the reduction of
pSMAD2 in PBMCs appears to be consistent with obser-
vations in galunisertib-treated animals (data not shown)
and ex vivo studies with human PBMCs or purified T
cells [10, 18] and suggests that the drug has the intended
pharmacological activity in patients.
In addition to these pharmacological effects in PBMCs,
we assessed the changes in inhibitor of DNA-binding
protein (ID1) and CD44 expression in pre- and post-
treatment tumor tissue of 1 patient who underwent surgi-
cal re-resection of his brain tumor during the off-period of
the intermittent dosing-regimen [4]. After treatment with
galunisertib, the expression of both ID1 and CD44 was
reduced, suggesting that TGF-β signaling was inhibited in
the glioma tissue.
Because galunisertib likely also affects the TGF-β signal-
ing in T regulatory cells [19], we used the T cell subsets as
another PDmarker for response. However, we did not observe
a change in the T cell subsets as described for ipilimumab,
which also targets T regulatory cells [20]. The lack of changes
in T regulatory cells during the monotherapy with galunisertib
does not preclude the possibility that changes are occurring in
Tcells. This is supported by the changes in pSMAD2 levels in
PBMCs from patients receiving galunisertib. Hence, function-
al immunemonitoring will be needed to better characterize the
effect of galunisertib on immune cells.
Among several plasma proteins, we observed that
patients with high baseline levels of MDC/CCL22 re-
ceived more than 6 cycles of treatment in both Part A
and Part B. The post-treatment levels of MDC/CCL22
did not show a change (data not shown). MDC/CCL22 is
associated with modulating T regulatory cells [21, 22]
and it may be involved in the activation of antigen-
presenting cells. Whether such levels confer a better
prognosis remains to be assessed. The lack of a change
in MDC/CCL22 may perhaps indicate that this chemo-
kine is not affected by galunisertib, but long-term exam-
inations will be needed to further confirm this initial
impression. Other plasma proteins were also found to
be at different levels for patients treated with ≥6 cycles
or ≤6 cycles. Their patterns of baseline levels were
consistent with previous reports, suggesting that they
were associated with prognosis in glioma, including
LDH [23], apolipoprotein CIII [24], ferritin [25], IL-8
[26], and VEGF [27].
The protein expression of pSMAD2 in tumor tissue was
assessed to determine whether high pSMAD2 expression was
present in this group of patients with glioma as previously
reported [28, 29]. Patients with longer treatment cycles had
lower baseline expression of pSMAD2 in their tumors.
Table 4 Summary of treatment responses (no clinical benefit was reported for patients in Part C)
Reasons Part A N=39 n (%) Part B N=26 n (%)
Cycles on study treatment, median (range) 2 (1–46) 2 (1–22)
Treatment response* n=30 n=26
CR/PR (%) 5 (16.7) 2 (7.7)
SD ≥6 cycles 1 (3.3) 4 (15.4)
CR/PR/SD ≥6 cycles 6 (20.0) 6 (23.1)*
SD 10 (33.3) 5 (19.2)
On study treatment at study closure in 2012 2 (6.7) 1 (3.8)
CR/PR/SD ≥6 cycles 6 6*
Primary 3 2
Low grade/secondary glioma 3 4
Treatment Responses by glioma grade and genetic mutation where tumor tissue was available (n=21)
IDH1/2 Other
Secondary or low grade glioma (n=8)
Clinical Benefit 4/8 0/8
No Clinical Benefit 1/8 3/8
Primary glioma (n=13)
Clinical Benefit 0/13 3/13
No Clinical Benefit 0/13 10/13
Abbreviations: CR complete response, PR partial response, SD stable disease
* Macdonald criteria for all but 1 patient, where RECISTwas used
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Whether pSMAD2 levels can be used as a future prog-
nostic or predictive marker is confounded by the fol-
lowing factors: First, pSMAD2 expression may change
over the course of the disease similar to other tumor-
associated markers in secondary glioma [30]. Since the
pSMAD2 staining was done only on the initial diagnos-
tic tissue and not on tissue before treatment with
galunisertib, the extent of TGF-β pathway activation
prior to the galunisertib treatment is unknown. For
example, radiotherapy is known to increase TGF-β ex-
pression [31, 32] and thus the subsequent pSMAD2
expression in patients could have increased during
first-line treatment with chemoradiation. Second, the
location of pSMAD2 expression is possibly related to
prognosis. In our study, we did not differentiate
pSMAD2 staining based on its anatomical location.
Using the same antibody as in the present study, high
expression in parenchymal cells was prognostic for sur-
vival, while perivascular staining was not [29]. Future
assessment of pSMAD2 staining will have to include
the differential evaluation of the staining patterns.
In summary, galunisertib has a predictable PK and a
favorable safety profile to continue its clinical investiga-
tion in Phase II studies and has shown clinical benefit at
the recommended dose predicted by a preclinical PK/PD
model.
Fig. 5 Plasma proteins at baseline. Each panel represents one plasma
biomarker displayed for each part (Part A and Part B). Comparison is
made between patients who received ≤6 cycles of treatment with those
who received ≥6 cycles of treatment. Comparison between both such
groups were performed within each part of the study and significance
shown on top of the bar graphs (unadjusted p-value): panel a: ferritin;
panel b: IL-8; panel c: apolipoprotein CIII; panel d: VEGF; panel e:
MDC/CCL22; panel f: LDH
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